NovaBioAssays is a contract research organization based in Greater Boston, specialized in innovative mass spectrometry solutions for drug discovery and development. The company offers a comprehensive suite of mass spectrometry services for quantitative and qualitative analysis of proteins and small molecules, including selective reaction monitoring/multiple reaction monitoring (SRM/MRM) for quantitative measurement of endo- and xeno-small molecules, peptides, oligonucleotides, and proteins in biological matrices. Additionally, they provide characterization and quantitation of complex protein molecules such as antibody-drug conjugate (ADC) and glycoproteins, and hydrogen deuterium exchange mass spectrometry for epitope mapping and biosimilar development. Founded in 2012, NovaBioAssays continues to make strides in the pharmaceutical research space, with a focus on cutting-edge mass spectrometry technologies. For more information, please visit http://novabioassays.com/Pages/Home.aspx
There is no investment information
No recent news or press coverage available for NovaBioAssays.
We care about your data, and we'd love to use cookies make your experience better.
